Projects per year
1983 PhD, Medical Microbiology, University of London. Thesis: Resistance mechanisms of Pseudomonas aeruginosa to ?-lactam antibiotics.
2003 State-Registered Clinical Scientist, Health Professions Council (CS1358).
David Livermore gained his BSc in 1978 and his PhD in 1983. He worked at the London Hospital Medical College from 1980 until 1997, when he joined the Health Protection Agency (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory in 1998. In October 2011, he became Professor of Medical Microbiology at UEA, but with 30% of this time supplied back to Public Health England as its Lead on Antibiotic Resistance.
Prof Livermore has broad interests on the evolution and dissemination of antibiotic resistance and its relationship to antibiotic prescribing. Beta-Lactamases are a particular interest, with recent work on the proliferation of ‘CTX-M’ extended-spectrum enzymes and carbapenemases, particularly NDM-1, which received extensive media coverage in 2010.
He sits on the British Society for Antimicrobial Chemotherapy working parties on resistance surveillance, multi-resistant pathogens and susceptibility testing and its Antibiotic Action advisory board, also on the Society for General Microbiology working group on sexually transmitted infections. He is also a member of the UK Government’s Antimicrobial Resistance and Healthcare Associated Infections Advisory Committee and has contributed extensively to the Chief Medical Offer for England’s Annual Report for 2011. He publishes and speaks widely on resistance and has edited for several journals including Journal of Antimicrobial Chemotherapy and Journal of Medical Microbiology and, currently, International Journal of Antimicrobial Agents.
Outside of work, he is a keen walker, has walked the perimeter of Norfolk and almost half the English Coastline.
9/78 to 6/80 QC Microbiology Devt., Wellcome Foundation, Dartford, Kent
6/80 to 8/97 Department of Medical Microbiology, London Hospital Medical College
6/80-11/83 Research Assistant
11/83-2/87 Postdoctoral Fellow (Wellcome Trust)
11/85-5/86 Secondment, Lecturer, University of Hong Kong
2/87-12/94 Lecturer in Medical Microbiology
12/94-8/97 Senior Lecturer in Medical Microbiology
9/97-9/00 Hon Senior Lecturer
9/98-10/11 Public Health England (formerly HPA), Microbiology Services
9/97-9/98 Head, Antibiotic Reference Unit, Colindale
9/98-date Director, Antibiotic Resistance Monitoring & Reference
10/11-date Professor of Medical Microbiology, University of East Anglia (primary employer, `70% time, with 30% of this subcontracted to Public Health England )
Lead on Antibiotic Resistance, Public Health England Microbiology Services, Colindale
Visiting Professor, King Saud University, Riyadh, Saudi Arabia
Honorary Professor of Medical Microbiology, Queen Mary University, London
Consultant on Antibiotic Resistance – advisory work for numerous diagnostic and pharmaceutical companies and potential investors
- Hon. Professor, Queen Mary, University of London, 2011-date
- Visiting Professor, King Saud University, Saudi Arabia, 2011-13
- Assistant Editor, Journal Antimicrobial Chemotherapy, 1987-90
- Editorial Board, European Journal of Clinical Microbiology, 1987-91
- Editor, Journal of Medical Microbiology, 1991-2003
- Editorial Board, Journal of Antimicrobial Chemotherapy, 1992-95
- Editorial Board, Antimicrobial Agents and Chemotherapy, 1996-date
- Editor, International Journal of Antimicrobial Agents, 2002-date
- Editorial Board, Korean Journal of Internal Medicine, 2011-date
- British Society for Antimicrobial Chemotherapy (BSAC) Working Party on Surveillance, 1997 - date
- BSAC, Working Party on Susceptibility Testing, 1997 - date
- Advisory Board of Asia-Pacific Research Foundation on Infectious Diseases, 1999 -date
- Organising committee of International Symposium on Antimicrobial Agents and Resistance (ISAAR), 1999-date
- UK Inter-Departmental Steering Group on ‘Resistance to Antibiotics and Other Antimicrobial Agents’, 1999-2002
- UK Government Specialist Advisory Committee on Antibiotic Resistance (SACAR), 2000-7
- Scientific Committee of 4th European Congress of Chemotherapy (Paris, May 2002), 2001-2
- Scientific Committee of 7th European Congress of Chemotherapy (Florence, October 2005), 2004-5
- European Commission Working Group on Antibiotic Resistance Genes in genetically modified organisms, 2003-4
- National Steering on Healthcare Associated Infection, 2004-7
- Joint British Society for Antimicrobial Chemotherapy/Hospital Infection Society working group on extended-spectrum #03b2-lactamases, 2005-6
- Advisor to Govt’s Antibiotic Resistance & Healthcare Associated Infection (ARHAI) committee on new resistance development / horizon scanning, 2007-13
- Member: UK Govt’s Antimicrobial Resistance & Healthcare Associated Infection (ARHAI) Advisory Committee, 2013-date
- European Committee on Antimicrobial Susceptibility Testing expert rules sub-group, 2008-10
- British Society for Antimicrobial Susceptibility Testing working party on the Urgent Need for New Antibiotics, 2009-10
- DEFRA Antibiotic Resistance Co-ordinating group (DARC), 2010-date
- Joint BSAC / British Infection Association / Infection Prevention Society Working Party on multiresistant pathogens, 2011-date
- Advisory Board for British Society for Chemotherapy Antibiotic Action Initiative, 2012-date
- Society for General Microbiology Expert Panel on Sexually Transmitted Infections2012-date
- CMO’s working group on genomics (Science Group), 2013
Key Research Interests and Expertise
My early research centred on ?-lactamases, and I showed how an apparently weak activity could protect a bacterium if the enzyme had high affinity and the ?-lactam permeated only slowly. This led to showing that models describing the interplay of ?-lactamase and permeability were adequate for Escherichia coli but not Pseudomonas aeruginosa, and I contributed to work revealing that this inadequacy was because P. aeruginosa also effluxes ?-lactams. Other early work explored the induction of AmpC ?-lactamases and the selection of AmpC-derepressed mutants from AmpC-inducible populations of Enterobacter and P. aeruginosa, showing selection to be the more important factor. I have been responsible for describing and investigating the properties of many new ?-lactamases, including those conferring resistance to carbapenems – the last reserve ?-lactams against many otherwise multiresistant bacteria.
My work increasingly spread from the mechanisms of resistance to its epidemiology. At the UK Health Protection Agency (Public Health England) I led groups that demonstrated the dramatic rises in MRSA in the late 1990s, ciprofloxacin-resistant gonococci around 2002-3, carbapenemase-resistant Acinetobacter spp. and cephalosporin-resistant E. coli from around 2003 and the recent rise in carbapenemases, partly linked to the repeated import of strains with NDM-1 enzyme via patients previously hospitalised in the Indian subcontinent.
My current major areas of research interest at UEA centre on the development of methods to rapidly detect antibiotic resistant bacteria in patient specimens. Such tests would allow the swifter optimisation of a patient’s therapy, benefitting both the individual and antibiotic stewardship – thus meeting key objectives highlighted in the Chief Medical Officer’s Annual Report for 2013. Other areas of interest are gut carriage of resistant bacteria and the relationship between in-vitro resistance and treatment outcome, Through on-going links with Public Health England I remain deeply involved in the surveillance of antibiotic resistance, the investigation of emerging resistance types and the in-vitro evaluation of new antibiotics against these organisms.
Research Keywords: Antibiotic resistance, ?-Lactamase, Carbapenem, Antibiotic development
Research Topics for PGR Supervision: Epidemiology of antibiotic resistance, Mechanisms of antibiotic resistance, Detection of antibiotic resistance
- Achaogen, Consultant2008-date
- Adenium, Scientific Advisory Board, 2013-date
- Allecra, Scientific Advisory Board, 2013-date
- Astellas - ad hoc advisory boards2007-date
- AstraZeneca - ad hoc advisory boards, 2009-date
- Bioversys, Scientific Advisory Board, 2013-date
- Curetis - ad hoc advisory boards2012-date
- Discuva, Scientific Advisory Board2011-date
- GlaxoSmithKline, Consultant, 2011-date
- Meiji, Consultant, 2011-date
- McKinsey - ad hoc advisory boards, 2010-date
- Roche - ad hoc advisory boards, 2012-date
- Tetraphase, Scientific Advisory Board, 2009-date
- Wockhardt, Global Clinical Council, 2013-date
In a research career of 30 years I have lecture widely and supervised or co-supervised 15 PhD student to successful completion. I currently supervise one PhD student, working on rapid microbiological investigation of urinary tract infections and co-supervise two others, one working on the strain structure of carbapenemase-producing Pseudomonas aeruginosa in the UK and the other on gen expression in P, aeruginosa biofilms.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Dive into details
Select a country/territory to view shared publications and projects
- 8 Finished
Development evaluation and implementation of molecular diagnostics for hospital-acquired and ventilator-associated pneumonia in diverse UK hospital settings
1/01/16 → 31/12/18
1/04/15 → 30/09/17
Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratoryMushtaq, S., Garello, P., Vickers, A., Woodford, N. & Livermore, D. M., Jun 2021, In: Journal of Antimicrobial Chemotherapy. 76, 6, p. 1511–1522 12 p.
Research output: Contribution to journal › Article › peer-review
Livermore, D. M., Feb 2021, In: Journal of Antimicrobial Chemotherapy. 76, 2, p. 434–442 9 p.
Research output: Contribution to journal › Article › peer-review7 Citations (Scopus)
Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteriaMushtaq, S., Vickers, A., Doumith, M., Ellington, M. J., Woodford, N. & Livermore, D., 1 Jan 2021, In: Journal of Antimicrobial Chemotherapy. 76, 1, p. 160–170 11 p.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile4 Citations (Scopus)
Livermore, D., 15 Jun 2021, In: JAC-Antimicrobial Resistance. 3, 1, p. i5–i16 12 p.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile21 Downloads (Pure)
Are resistance rates among bloodstream isolates a good proxy for other infections? Analysis from the BSAC Resistance Surveillance ProgrammeHorner, C., Mushtaq, S., Allen, M., Longshaw, C., Reynolds, R. & Livermore, D. M., Jul 2021, In: Journal of Antimicrobial Chemotherapy. 76, 7, p. 1822–1831 10 p.
Research output: Contribution to journal › Article › peer-review